PURPOSE: The purpose of this study was to assess the safety, local control, and oncologic efficacy of percutaneous ablation in treatment of metastatic RCC (mRCC).
MATERIALS AND METHODS: A retrospective review was performed of 61 patients who underwent 74 ablation procedures to treat 82 mRCC lesions with intent of local eradication. Technical success, local tumor control, complications, and patient survival were analyzed according to standard criteria.
RESULTS: Four (4.9%) technical failures were observed while two patients were lost to follow up. Time to recurrence was assessed for the subset of 76 (93%) tumors that were followed post ablation. Six (of 76, 7.9%) tumors recurred at a mean of 1.6 years following ablation (median 1.4; range 0.6-2.9); thus, known overall local tumor control was achieved in 70/80 (87.5%) of tumors. Estimated local recurrence-free survival rates (95% CI; number still at risk) at 1, 2, and 3 years following ablation were 94% (88 - 100; 41), 94% (88 - 100; 32), and 83% (70 - 97; 17), respectively. Estimated overall survival rates (95% CI; number still at risk) at 1, 2, and 3 years following ablation were 87% (79 - 97; 42), 83% (73 - 94; 31), 76% (63 - 90; 19), respectively.
CONCLUSION: Image guided ablation of mRCC is a relatively safe procedure with acceptable local control rates. Ablation may offer patients a minimally invasive option of local tumor eradication and warrants a role in the multimodal treatment approach for select patients.
Written by:
Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Are you the author?
Mayo Clinic. ; ; ; ; ; ; ; ; ; ; ; ;
Reference: J Urol. 2014 Mar 11. pii: S0022-5347(14)02919-X.
doi: 10.1016/j.juro.2014.03.006
PubMed Abstract
PMID: 24631107
UroToday.com Renal Cancer Section
